Therapeutic strategies for neurodegenerative disorders have commonly targeted individual
aspects of the disease pathogenesis to little success. Neurodegenerative diseases …

The development of new therapeutic approaches to diseases relies on the identification of
key molecular targets involved in amplifying disease processes. One such molecule is …

It has become widely accepted that inflammation is a driving force behind a variety of
chronic diseases, such as cardiovascular disease, diabetes, kidney disease, cancer …

Alzheimer's disease (AD) is the most common neurodegenerative disease characterized by
extracellular deposition of amyloid beta (Aβ) leading to cognitive decline. Evidence from …

The role of Akkermansia muciniphila, one of the most abundant microorganisms of the
intestinal microbiota, has been studied extensively in metabolic diseases, such as obesity …

Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and
dipeptidyl peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 …

The decline in cognitive function and the prevalence of neurodegenerative disorders are
among the most serious threats to health in old age. The prevalence of dementia has …

Abstract Type 2 diabetes (T2D) and its target organ injuries cause distressing impacts on
personal health and put an enormous burden on the healthcare system, and increasing …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …

Metformin reduces insulin resistance, which constitutes a pathophysiological connection of
diabetes with Alzheimer's disease (AD), but the evidence of metformin on AD development …